Navigation Links
Amicus Therapeutics Opens Research Facility in San Diego
Date:9/15/2008

CRANBURY, N.J. and SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced that the company has leased laboratory space for a focused, small scale research facility in San Diego. The facility will be used to support ongoing research into new applications of the company's platform technology.

"With proof of concept for pharmacological chaperones now established, research at the San Diego facility will support Amicus' efforts to expand our early stage pipeline," said David Lockhart, Ph.D., chief scientific officer for Amicus Therapeutics. "Locating the new laboratory in San Diego allows us to complement and expand our existing research capabilities in Cranbury by tapping into the significant resources and expertise of the San Diego science and biotechnology community."

"We believe pharmacological chaperones have significant potential to treat a broad range of genetic diseases," added John Crowley, president and CEO of Amicus. "The focus of our research efforts in San Diego will be to assess new chaperone applications in diseases with high unmet medical needs and larger patient populations particularly in the areas of neurodegenerative and metabolic disorders. This small scale facility will complement our core research and development activities in New Jersey."

The new laboratory space was included in Amicus' operating plan and budget for 2008 as part of increased investment in research beyond the lysosomal storage disorders. Amicus expects to begin occupying the space immediately.

About Amicus Therapeutics

Amicus Therape
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Columbia, Md. (PRWEB) August 19, 2014 ... integrated liquid chromatography systems, Prominence-i and Nexera-i, adding ... UHPLC systems. Combining excellent functionality, an intuitive operating ... performance and a more efficient workflow for conventional ... systems feature innovative, intuitive and intelligent design so ...
(Date:8/19/2014)... Cellgen Diagnostics today launched ... a corporate lab for its genetic-based medical testing ... a critical component in the move from today’s ... of personalized medicine – a more predictive, preventive, ... contributions will support Cellgen’s intent to develop the ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 XenoTech ... fast and cost-effective metabolite production from bioactive small ... chemistry platform, the technology enables convenient and timely ... According to XenoTech’s Vice President of Commercial Operations, ... for assessing clinical risk can be measured directly ...
(Date:8/19/2014)... 19, 2014 In November 2012, the European ... Evaluation Report (PBRER) in a new PSUR – responding to ... benefit-risk profile of a drug. Adopted in many regions, the ... Present a comprehensive and critical analysis of new or ... Highlight any new evidence of the potential benefits of ...
Breaking Biology Technology:Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2
... DALLAS, May 7 Entrust, Inc. (Nasdaq: ENTU ... the 8th Annual,State of Technology Luncheon on Thursday, May ... Dallas, Texas., Conner will address the history of ... evolved to address the growing threats.,Conner also will discuss ...
... today announced,the first single port laparoscopic removal of ... Anthony Discuillo and Christopher Awtry performed the procedure ... System creates an,invisible barrier that does not rely ... the cavity without loosing intra-abdominal pressure,enabling surgeons to ...
... leading contract research,organization Pharm-Olam International (POI, http://www.pharm-olam.com ),upgraded ... (VoIP),system that would better serve the company,s global communications ... initially selected a local vendor to plan, develop and ... solution was a bigger problem,than the old PBX., ...
Cached Biology Technology:Entrust Chairman, President and CEO Bill Conner to Present at 8th Annual State of Technology Luncheon 2SurgiQuest Announces First Single Port Procedure for Ovary Removal Using AirSeal(TM) Access System 2Pharm-Olam Finds VoIP Solution in Taridium LLC 2
(Date:8/20/2014)... grows to about 4,000 members, it triggers an important ... a special type of comb used for rearing male ... Department of Neurobiology and Behaviour at Cornell University, led ... of honeybee colonies. The results are published in Springer,s ... , Reproduction isn,t always a honeybee colony,s top ...
(Date:8/20/2014)... DENVER , Aug. 20, 2014  The ... take place in Tampa, Florida ... interactive sessions with Steven Rahman, Director, Technology and Strategy ... Sector at Experian. The theme of this year,s ... and Privacy. "Biometrics UnPlugged: Mobility ...
(Date:8/19/2014)... in German . ... sources. If a large amount of electricity is to be ... will have to be stored during productive periods so that ... are far from adequate for the purpose. Science and industry ... lies on battery systems that used to be too expensive ...
Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3
... interdisciplinary perspective. Presenters at the National Academy of Sciences, ... ways to identify, encourage, and support advances in climate ... other fields. In addition, U.S. Secretary ... Sackler Lecture beginning at 6 p.m. on March 31 ...
... Providing further understanding of the link between low birth ... deprived newborns are "programmed" to eat more because they ... that controls food intake, according to an article published ... The study by a team of researchers at Los ...
... of people commit suicide worldwide each year, researchers and ... person,s likelihood of thinking about or trying to commit ... Hospital del Mar Research Institute (IMIM) has participated, has ... suicides. "It is of key importance to identify suicidal ...
Cached Biology News:Study provides explanation for connection between low birth weight and obesity later in life 2First international index developed to predict suicidal behavior 2
...
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The 10-user network license entitles ten users to access data f...
Mouse monoclonal antibody raised against a partial recombinant JRKL. NCBI Entrez Gene ID = JRKL...
Mouse monoclonal antibody to ST8SIA2 - ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2...
Biology Products: